SonKRd treatment for newly diagnosed multiple myeloma with t(11;14)
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of four drugs (called SonKRd) for people newly diagnosed with multiple myeloma who have a specific genetic change (t(11;14)) and are eligible for a stem cell transplant. The goal is to see how well this treatment works and whether it can help control the disease before and after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with active multiple myeloma (a blood cancer).
- You are 18 years or older.
- Your bone marrow test (FISH) shows a specific genetic change called t(11;14).
- You have not yet had treatment for myeloma besides supportive care like pain relief.
- You are in fairly good health and able to care for yourself (ECOG score 0–2).
- Your organs (like kidney, liver, blood counts) are working well enough according to the study's limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This trial tests a new way to treat multiple myeloma after a stem cell transplant. It uses a combination of drugs (KPD) to help keep the disease from coming back.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.